Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

3.09USD
4:00pm EDT
Change (% chg)

$0.03 (+0.98%)
Prev Close
$3.06
Open
$3.08
Day's High
$3.11
Day's Low
$3.04
Volume
143,534
Avg. Vol
381,991
52-wk High
$5.11
52-wk Low
$2.86

CLDX.OQ

Chart for CLDX.OQ

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.85
Market Cap(Mil.): $382.82
Shares Outstanding(Mil.): 125.10
Dividend: --
Yield (%): --

Financials

  CLDX.OQ Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -1.20 -- --
ROI: -42.03 2.29 -5.84
ROE: -50.45 0.06 -5.23

BRIEF-Celldex reports Q1 loss per share $0.28

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 09 2017

BRIEF-COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 5.1 PCT PASSIVE STAKE IN CELLDEX THERAPEUTICS AS OF DEC 31, 2016

* COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS A 5.1 PERCENT PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2lwtvZF) Further company coverage:

Feb 10 2017

BRIEF-Celldex Therapeutics files for offering of up to 18.4 mln shares of common stock

* Files for offering of up to 18.4 million shares of common stock by the selling stockholders Source text : (http://bit.ly/2kpoaTY) Further company coverage:

Jan 26 2017

More From Around the Web

Earnings vs. Estimates